Asset Details
Do you wish to reserve the book?
Chronotherapy with Empagliflozin in Patients with Type-2 Diabetes Mellitus Causes Better Response on Evening Administration
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Chronotherapy with Empagliflozin in Patients with Type-2 Diabetes Mellitus Causes Better Response on Evening Administration
Do you wish to request the book?
Chronotherapy with Empagliflozin in Patients with Type-2 Diabetes Mellitus Causes Better Response on Evening Administration
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Chronotherapy with Empagliflozin in Patients with Type-2 Diabetes Mellitus Causes Better Response on Evening Administration
2024
Overview
Background: Diabetes mellitus is associated with hyperglycemia, oxidative stress and an increased risk of cardiovascular disease (CVDs). Administration of empagliflozin (EMPA) reduces blood glucose and blood pressure. Evidence is scarce regarding its role in chronotherapy. This observational study examines the effect of EMPA as chronotherapy in patients with type 2 diabetes mellitus (T2DM). Subjects and Methods: This study included 63 subjects with T2DM, scheduled to receive EMPA. Of these, 57 received EMPA (25mg/day) for 24 weeks, of which 25 received the dose in the evening and 23 in the morning. Clinical data, dietary intake and physical activity were assessed using validated questionnaires. Blood pressures were measured by sphygmomanometer. Single blind therapy with EMPA was associated with a significant reduction in fasting and 2-hour postprandial blood glucose levels and HbAlc. These changes were greater when EMPA was administered in the evening compared to morning. The reductions in pro-inflammatory cytokines, C-reactive proteins, TNF-alpha and interleukin-6, also showed greater and reductions when EMPA was administered in the evening, compared to morning and baseline levels. Chronotherapy with EMPA also caused a non-significant reduction in serum uric acid, systolic and diastolic blood pressures and angiotensin converting enzyme (ACE) levels when given in the evening compared to those patients who received EMPA in the morning, Conclusion: Chronotherapy with EMPA causes a greater reduction in blood glucose, blood pressures, serum uric acid, HbAlc, cytokines and ACE when administered in the evening compared to values obtained when the same dose was administered in the morning. Randomized, controlled intervention trials should be carried out to confirm these observations.
